about
Updates on the management of diabetes in dialysis patientsElimination of endogenous toxin, creatinine from blood plasma depends on albumin conformation: site specific uremic toxicity & impaired drug bindingDementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies.Neurological complications in chronic kidney disease patients.Kidney-brain crosstalk in the acute and chronic setting.Cognitive Impairment in Chronic Kidney Disease: Vascular Milieu and the Potential Therapeutic Role of Exercise.Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3.Kidney disease as a determinant of cognitive decline and dementia.Diffuse interstitial brain edema in patients with end-stage renal disease undergoing hemodialysis: a tract-based spatial statistics study.Chronic renal failure induces cell death in rat hippocampal CA1 via upregulation of αCaMKII/NR2A synaptic complex and phosphorylated GluR1-containing AMPA receptor cascades.Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety!Liver transplantation prevents progressive neurological impairment in argininemiaSevere Decline of Estimated Glomerular Filtration Rate Associates with Progressive Cognitive Deterioration in the Elderly: A Community-Based Cohort Study.Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality.Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders.Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins.Albuminuria is associated with a higher prevalence of depression in a population-based cohort study: the Maastricht Study.Chronic kidney disease-related physical frailty and cognitive impairment: a systemic review.Uraemia: an unrecognized driver of central neurohumoral dysfunction in chronic kidney disease?Neuroinflammation in liver disease: sessional talks from ISHEN.Predominant gray matter volume loss in patients with end-stage renal disease: a voxel-based morphometry study.Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Aberrant cortical thickness in neurologically asymptomatic patients with end-stage renal disease
P2860
Q27024782-2E1381EA-82DE-43C2-B8B9-4B2B72C56A50Q28477294-11DE8E83-814F-4684-BECC-0282D2FFC16AQ30240101-D1DBEEF9-BB19-4B79-BBEB-7F3D637D4270Q30252095-41A8C19C-D2F3-42F1-899C-8A36477745D3Q30278845-BDC214D8-932C-4001-AA13-BB5ED5DB7B68Q33630922-EF13B56E-0B70-41AF-A650-D4A33899825BQ34846428-92B1888D-6AB2-47A0-A152-C4AC6CBD11F5Q35180274-37A9934D-7AA1-4CE4-99E3-D5982DCD2B23Q36153936-04C4B47A-6C11-43BF-9278-871C690C0469Q36466024-2DF4B12B-06E9-45AE-A5D1-E4666740E3E8Q37025558-5948F2C9-C197-4A40-ABF4-BB02F0E2C6E4Q37127600-CAC82C34-4C42-4FCB-B2E9-C01432923E50Q37648683-48DA6CE3-4C25-4404-92F9-70D2A8C3417DQ37828505-ED6D379F-CE5D-4990-A363-68E3C247085BQ37847248-65DBCAFB-739F-4B28-BF27-CA537603D7DAQ37879580-3BA40AD4-1807-40B5-A0C4-9CCA0F757F10Q38783172-BE51EA4C-89E6-4CC5-AE29-D2CA43312B70Q38848257-8B5CE778-639A-4714-80EC-5993AE0B028AQ38849711-5D556115-CDF6-46FF-AAF5-17AB567862AFQ38977487-89228968-DADD-4D69-BDFE-ED091D11D7B9Q46549434-0F9CCB4F-3CF0-494C-A332-058E4B7DA1D6Q47216784-2E1064B4-296F-44C2-A834-99A7B5FEA927Q58803507-76053C09-E6F5-4035-8195-D1CE159D0750
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guanidino compounds as uremic (neuro)toxins.
@en
Guanidino compounds as uremic
@nl
type
label
Guanidino compounds as uremic (neuro)toxins.
@en
Guanidino compounds as uremic
@nl
prefLabel
Guanidino compounds as uremic (neuro)toxins.
@en
Guanidino compounds as uremic
@nl
P2093
P1433
P1476
Guanidino compounds as uremic (neuro)toxins.
@en
P2093
Griet Glorieux
Peter Paul De Deyn
Sunny Eloot
P304
P356
10.1111/J.1525-139X.2009.00577.X
P577
2009-07-01T00:00:00Z